Mucosal immunity to poliovirus

Mucosal Immunol. 2022 Jan;15(1):1-9. doi: 10.1038/s41385-021-00428-0. Epub 2021 Jul 8.


A cornerstone of the global initiative to eradicate polio is the widespread use of live and inactivated poliovirus vaccines in extensive public health campaigns designed to prevent the development of paralytic disease and interrupt transmission of the virus. Central to these efforts is the goal of inducing mucosal immunity able to limit virus replication in the intestine. Recent clinical trials have evaluated new combined regimens of poliovirus vaccines, and demonstrated clear differences in their ability to restrict virus shedding in stool after oral challenge with live virus. Analyses of mucosal immunity accompanying these trials support a critical role for enteric neutralizing IgA in limiting the magnitude and duration of virus shedding. This review summarizes key findings in vaccine-induced intestinal immunity to poliovirus in infants, older children, and adults. The impact of immunization on development and maintenance of protective immunity to poliovirus and the implications for global eradication are discussed.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Neutralizing / blood
  • Antibodies, Viral / blood
  • Child
  • Humans
  • Immunity, Mucosal
  • Immunoglobulin A / blood
  • Poliomyelitis / immunology*
  • Poliovirus / physiology*
  • Vaccination
  • Viral Vaccines / immunology*
  • Virus Shedding


  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin A
  • Viral Vaccines